Myriad Genetics (MYGN) Expected to Announce Quarterly Earnings on Monday

Myriad Genetics (NASDAQ:MYGN) is expected to be posting its Q4 2025 results after the market closes on Monday, February 23rd. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $207.5650 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:30 PM ET.

Myriad Genetics Trading Down 2.1%

Shares of NASDAQ:MYGN opened at $4.29 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.33 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $399.87 million, a P/E ratio of -0.99 and a beta of 1.90. Myriad Genetics has a 12-month low of $3.76 and a 12-month high of $15.18. The firm has a fifty day moving average of $5.83 and a two-hundred day moving average of $6.65.

Hedge Funds Weigh In On Myriad Genetics

Several institutional investors and hedge funds have recently modified their holdings of MYGN. Alliancebernstein L.P. raised its holdings in shares of Myriad Genetics by 1.8% in the third quarter. Alliancebernstein L.P. now owns 101,234 shares of the company’s stock valued at $732,000 after purchasing an additional 1,784 shares during the last quarter. Legal & General Group Plc grew its holdings in Myriad Genetics by 1.0% during the second quarter. Legal & General Group Plc now owns 237,688 shares of the company’s stock worth $1,262,000 after purchasing an additional 2,313 shares during the period. Quarry LP increased its holdings in shares of Myriad Genetics by 155.6% during the 4th quarter. Quarry LP now owns 4,365 shares of the company’s stock worth $27,000 after acquiring an additional 2,657 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of Myriad Genetics by 2.7% in the fourth quarter. Franklin Resources Inc. now owns 103,374 shares of the company’s stock valued at $636,000 after purchasing an additional 2,714 shares during the last quarter. Finally, Royal Bank of Canada grew its stake in Myriad Genetics by 129.6% in the 4th quarter. Royal Bank of Canada now owns 4,993 shares of the company’s stock valued at $31,000 after buying an additional 2,818 shares during the last quarter. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MYGN has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday, December 29th. TD Cowen reissued a “hold” rating on shares of Myriad Genetics in a report on Tuesday, November 4th. UBS Group upped their price objective on Myriad Genetics from $6.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Wells Fargo & Company increased their price objective on Myriad Genetics from $6.00 to $6.50 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Finally, Piper Sandler dropped their target price on Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating for the company in a research report on Tuesday, November 11th. Four investment analysts have rated the stock with a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Myriad Genetics has an average rating of “Hold” and an average price target of $9.44.

Myriad Genetics Company Profile

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.